Although identifying cancer-subtype biomarker is challenging, UALCAN analysis suggested that the methylation of the PRKY promoter is absent in many other cancers (lung, liver, colorectal, esophageal, bladder, and pancreatic cancers). This evidence concerns the gene PRKY and pancreatic neoplasm.